查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602822

抗驚厥藥物市場：依藥物類型、適應症分類 - 全球預測 2025-2030

Anticonvulsants Market by Drug types (AMPA, Barbiturate, Benzodiazepine), Indication (Anxiety, Bipolar Disorder, Borderline Personality Disorder) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗驚厥藥市值為120.3億美元，預計到2024年將達到130.7億美元，複合年成長率為8.71%，到2030年將達到215.9億美元。

抗驚厥藥，也稱為抗癲癇藥，是主要用於預防和治療與癲癇相關的癲癇發作的藥物，也用於治療雙相情感障礙、偏頭痛和神經病變疼痛。對抗驚厥藥物的需求源自於神經系統疾病的日益普及以及對此類疾病進行有效管理的需要。這些藥物廣泛用於醫院、診所和居家醫療機構，為癲癇和其他神經系統疾病患者提供重要的治療選擇。對於醫療保健提供者和患者來說，最終用途範圍已顯著擴大，支持了有關藥物依從性和副作用管理的可近性和患者教育的需求。市場成長主要是由藥物發現的技術進步、診斷能力的提高以及對這些藥物的認知和接受度的提高所推動的。此外，新型製劑和聯合治療的逐漸出現為市場滲透提供了潛在的機會。然而，嚴格的法律規範、潛在的副作用和高昂的治療成本等挑戰可能會阻礙市場成長。抗藥性癲癇的適當治療仍存在重大差距，凸顯了創新和研究的潛在領域。此外，利用人工智慧開發個人化醫療方法和藥物開發可以為業務成長開闢新的途徑，旨在提高療效並最大限度地減少副作用。鑑於抗驚厥藥物市場的性質，公司應優先考慮策略夥伴關係關係、先進研發投資以及市場多元化，以保持相關性。經皮吸收貼片和鼻噴劑等給藥方法的持續創新，以及對新作用機制的探索，正在顯著影響市場動態，推動成長並解決神經治療領域未滿足的需求。

主要市場統計
基準年[2023] 120.3億美元
預測年份 [2024] 130.7億美元
預測年份 [2030] 215.9億美元
複合年成長率（%） 8.71%

市場動態：揭示快速發展的抗驚厥藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗驚厥藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 年輕人和老年族群中癲癇盛行率不斷上升
    • 政府措施不斷採取措施來支持癲癇意識
    • 擴大用於治療癲癇以外的疾病
  • 市場限制因素
    • 疼痛管理替代方案的可用性
  • 市場機會
    • 抗癲癇藥物的監管核准增加
    • 推出新一代抗癲癇藥物
  • 市場問題
    • 供不應求與二代藥專利到期

波特五力：駕馭抗驚厥藥物市場的策略工具

波特五力：框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗驚厥藥物市場的外部影響

外部宏觀環境因素在塑造抗驚厥藥物市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解抗驚厥藥物市場的競爭格局

抗驚厥藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：抗驚厥藥物市場供應商績效評估

FPNV定位矩陣是評估抗驚厥藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製抗驚厥藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，抗驚厥藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 年輕人和老年人的癲癇盛行率增加
      • 政府努力支持提高癲癇意識
      • 擴大用於非癲癇疾病的治療
    • 抑制因素
      • 疼痛管理替代方案的可用性
    • 機會
      • 抗驚厥藥物的監管核准增加
      • 新一代抗癲癇藥物的出現
    • 任務
      • 供不應求及二代藥專利到期
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 抗驚厥藥物市場：依藥物類型

  • 介紹
  • AMPA
  • 巴比妥酸
  • 苯二氮平類
  • 氨基甲酸酯氨基甲酸酯抗驚厥藥
  • 碳酸酐酶抑制劑
  • 二苯並氮卓
  • 三嗪

第7章 抗驚厥藥物市場：依適應症分類

  • 介紹
  • 焦慮
  • 躁鬱症
  • 邊緣性人格障礙
  • 癲癇
  • 纖維肌痛
  • 偏頭痛
  • 神經病變疼痛

第8章美洲抗驚厥藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太抗驚厥藥市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲抗驚厥藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Astrazeneca PLC
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lifecare Neuro Products Limited
  • Lundbeck A/S
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited
Product Code: MRR-ED54C46E8048

The Anticonvulsants Market was valued at USD 12.03 billion in 2023, expected to reach USD 13.07 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 21.59 billion by 2030.

Anticonvulsants, also known as antiepileptic drugs, are medications primarily used to prevent and treat seizures associated with epilepsy but are also used for bipolar disorder, migraines, and neuropathic pain. The necessity for anticonvulsants stems from the increasing prevalence of neurological disorders and the need for effective management of such conditions. These medications find broad application across hospitals, clinics, and homecare settings, offering critical therapeutic options for patients with epilepsy and other neurological conditions. The end-use scope largely extends to healthcare providers and patients, underlining the need for accessibility and patient education regarding medication adherence and side effects management. Market growth is significantly influenced by technological advancements in drug discovery, an increase in diagnostic capabilities, and heightened awareness and acceptance of these medications. Moreover, the progressive emergence of novel drug formulations and combination therapies offers potential opportunities for deeper market penetration. However, challenges such as stringent regulatory frameworks, potential side effects, and the high cost of treatment may hamper market growth. There is still a notable gap in adequate treatment for drug-resistant forms of epilepsy, highlighting a potential area for innovation and research. Furthermore, developing personalized medicine approaches and leveraging artificial intelligence for drug development could present new avenues for business growth, aiming to increase efficacy and minimize adverse effects. Given the nature of the anticonvulsants market, characterized by a competitive landscape with numerous players focusing on R&D and mergers, businesses must prioritize strategic partnerships, investment in advanced R&D, and market diversification to stay relevant. Continuous innovation in delivery methods, like transdermal patches or intranasal sprays, and exploring novel mechanisms of action can significantly influence market dynamics, propelling growth and addressing unmet needs in neurological treatment.

KEY MARKET STATISTICS
Base Year [2023] USD 12.03 billion
Estimated Year [2024] USD 13.07 billion
Forecast Year [2030] USD 21.59 billion
CAGR (%) 8.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticonvulsants Market

The Anticonvulsants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of epilepsy among young and senior population
    • Rising government initiatives supporting epilepsy awareness
    • Expanding use in treating nonepileptic conditions
  • Market Restraints
    • Availability of substitutes options for pain management
  • Market Opportunities
    • Rising drug approvals of anticonvulsant drugs from regulatory bodies
    • Emergence of new-generation antiepileptic drugs
  • Market Challenges
    • Drug supply shortage and patent expiration of the second-generation drugs

Porter's Five Forces: A Strategic Tool for Navigating the Anticonvulsants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticonvulsants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticonvulsants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticonvulsants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticonvulsants Market

A detailed market share analysis in the Anticonvulsants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticonvulsants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticonvulsants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticonvulsants Market

A strategic analysis of the Anticonvulsants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticonvulsants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Dr. Reddy's Laboratories Limited, Eisai Co., Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lifecare Neuro Products Limited, Lundbeck A/S, Mankind Pharma Ltd., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Anticonvulsants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug types, market is studied across AMPA, Barbiturate, Benzodiazepine, Carbamate Anticonvulsants, Carbonic Anhydrase Inhibitor, Dibenzazepine, and Triazine.
  • Based on Indication, market is studied across Anxiety, Bipolar Disorder, Borderline Personality Disorder, Epilepsy, Fibromyalgia, Migraine, and Neuropathic Pain.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of epilepsy among young and senior population
      • 5.1.1.2. Rising government initiatives supporting epilepsy awareness
      • 5.1.1.3. Expanding use in treating nonepileptic conditions
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of substitutes options for pain management
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
      • 5.1.3.2. Emergence of new-generation antiepileptic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Drug supply shortage and patent expiration of the second-generation drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anticonvulsants Market, by Drug types

  • 6.1. Introduction
  • 6.2. AMPA
  • 6.3. Barbiturate
  • 6.4. Benzodiazepine
  • 6.5. Carbamate Anticonvulsants
  • 6.6. Carbonic Anhydrase Inhibitor
  • 6.7. Dibenzazepine
  • 6.8. Triazine

7. Anticonvulsants Market, by Indication

  • 7.1. Introduction
  • 7.2. Anxiety
  • 7.3. Bipolar Disorder
  • 7.4. Borderline Personality Disorder
  • 7.5. Epilepsy
  • 7.6. Fibromyalgia
  • 7.7. Migraine
  • 7.8. Neuropathic Pain

8. Americas Anticonvulsants Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anticonvulsants Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anticonvulsants Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astrazeneca PLC
  • 3. Bausch Health Companies Inc.
  • 4. Biocon Limited
  • 5. Cadila Pharmaceuticals Limited
  • 6. Cipla, Inc.
  • 7. Dr. Reddy's Laboratories Limited
  • 8. Eisai Co., Ltd.
  • 9. GlaxoSmithKline PLC
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. Jazz Pharmaceuticals, Inc.
  • 12. Johnson & Johnson Services, Inc.
  • 13. Lifecare Neuro Products Limited
  • 14. Lundbeck A/S
  • 15. Mankind Pharma Ltd.
  • 16. Merck KGaA
  • 17. Novartis AG
  • 18. Novo Nordisk A/S
  • 19. Otsuka Pharmaceutical Co., Ltd.
  • 20. Pfizer Inc.
  • 21. Sanofi S.A.
  • 22. Sunovion Pharmaceuticals Inc.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICONVULSANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICONVULSANTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. INDONESIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. INDONESIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. JAPAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 49. JAPAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 51. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 53. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 55. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. TAIWAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 59. TAIWAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. THAILAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. THAILAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. VIETNAM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 63. VIETNAM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. DENMARK ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 68. DENMARK ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. EGYPT ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 70. EGYPT ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FINLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 72. FINLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 74. FRANCE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 76. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ISRAEL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 78. ISRAEL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 80. ITALY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 82. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NIGERIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 84. NIGERIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. NORWAY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 86. NORWAY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. POLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. POLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 90. QATAR ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 92. RUSSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 94. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. SPAIN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWEDEN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 100. SWEDEN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 102. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. TURKEY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 104. TURKEY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 110. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023